Froner Cytobiological Therapies Internaonal

THE ANSWER

to treatment of chronic, incurable or untreatable

diseases, ageing diseases and general rejuvenaon

2018 Handbook © FCTI (Germany)

Precursor (Progenitor) Stem Cell Therapy

Autologous Stem Cell Therapy

Acve Speciﬁc Immunotherapy

ABOUT FCTI

FCTI is an adapve, regenerave medical

innovaons organisaon delivering

therapeuc soluons for praconers

managing paents with untreatable

diseases, condions or syndromes and

those deemed no longer treatable by

contemporary healthcare.

FCTI is a froner research and

development organisaon, earning and

learning a knowledge base in precursor

stem cells for xenotransplantaon and

stem cell culturing for autologous

transplant.

FCTI is a world leader in the manufacture

of precursor stem cells from a state of the

art European Union laboratory, delivering

for praconers around the world.

Connuous FCTI parallel research

programs with partners, advisers,

contractors and in-house specialists

enabled new discoveries in primary ssue

culturing. Clinical experience from our

network of praconers unlocked

methodologies for applicaon in new

advanced therapies.

FCTI has evolved from product provider to

therapeuc service delivery. In 2016, to

reﬂect this, we changed our name to

Froner Cytobiological Therapies

Internaonal.

Our revoluon for evoluonary therapy.

Froner Cytobiological Therapies Internaonal

The new normal for science and medicine

changes second by second, hour by hour,

day by day. It is moving fast.

The thirst for knowledge, the quest for

discovery moves exponenally faster as

each day dawns and along with it, and the

pace of change in this modern digital world

is rapid and relentless.

Two disnct, but very diﬀerent challenges

accompany this progress. New diseases of

the modern world are emerging as we are

exposed to more and more visible toxins in

our environment and invisible toxins in our

modern and increasingly processed diet.

Long idenﬁed disease, syndromes and

condions have opportunity for new

soluons; parcularly those deemed too

hard, too expensive or impossible to treat.

The research and clinical pracce in

ﬁnding soluons using cells themselves

began with some success in Western

Europe during the great depression.

A world war and a baby boom later, the

stem cell was discovered and, with it, the

race began to unlock the stem cell’s

regenerave healing biological power. It

took unl the 1980’s for it to become part

of the modern lexicon. It was the 1990’s

before the importance of this discovery

was widely understood and for religious

and cultural, moral and ethical issues to be

debated.

In the new millennium, it became a –

mostly incorrect – catch cry in markeng

for aesthec products that set back public

percepon and saw a myriad of new laws

governing research and applicaon. Now,

decades of contemporary research, clinical

and case studies have seen remarkable

breakthroughs in therapies for new

diseases of the modern world and old

diseases le untreated.

FCTI

• Premium Source • Source Safety

• World Leading Tissue Culture Technology

• Cell Therapy Principles

• Immune System • Immune System Disorders

• Blood for An Ageing and early stage cancer

• Tumour ssue for late stage cancer

• Autologous Stem Cell Therapy

• Consult • Culturing & Preparaon • Implantaon

• Post care

STEM CELLS THERAPY

FCTI Therapies

PSCT Precursor Stem Cell Therapy 4

PSCT Precursor Stem Cell Therapy

PSCT Cell Types 6

PSCT Indicaons 7

PSCT Ausm & Down Syndrome 8

PSCT Diabetes & Cerebral Palsy

PSCT Parkinson’s, Age Related, Heart

PSCT Liver & Kidney 11

ASCT

Autologous Stem Cell Therapy &

Producon Process

PSCT Producon Process 12

ASI Immunology

ASI Indicaons

ASI Producon Process & Applicaon

ASI Acve Speciﬁc Immunotherapy

• Historical use • Precursor Stem Cells

• PSCT • ASCT • ASI

• Comparave Analysis of Precusor Stem Cells

with other Stem Cells

• FCTI ASI Therapy

Page

Contents

Stem Cell Therapy (SCT) is a minimally

invasive therapeuc procedure where the

live stem cells from human (allo-) or animal

(xeno-) origin are implanted to the

recipient and due to its mul-potency and

restorave funcon, stem cell therapy is

an outstanding therapy technology that

addresses mulple funconal

requirements of diﬀerent vital organs and

ssues and for the treatment of chronic

disease.

Transplanted cells bring life back by

replenishing or repairing the cells of

damaged organs. It eﬀecvely restores

ssues and organs by smulang the

innate repair system of damaged cells,

acvang the growth funcon of dormant

cells and replacing degraded,

malfunconing cells. In other words, Stem

Cell Therapy may potenally be used when

convenonal treatments are no longer

eﬀecve.

When the stem cells come from a donor of

the same species it is called allogenic cell

therapy. When the stem cells come from

your own blood or ssue it is known as

autologous – or self – therapy. When the

stem cells are derived from a diﬀerent

species it is called xenogenic therapy.

STEM CELL THERAPY

A forerunner of modern regenerave

medicine, Stem Cell Therapy has been

ulised successfully in Europe in some

form or another for almost 80 years.

Clinical data from paents – principally in

Germany and Switzerland – has been

consolidated and conclusive regarding the

safety and eﬀecveness of these stem cell

based treatments.

HISTORICAL USE

PRECURSOR STEM CELLS

Precursor Stem Cells are parally

diﬀerenated stem cells that are procured

from animal fetus once at the stage of

organogenesis. These mul-potent stem

cells are therefore commied to follow a

predetermined path of diﬀerenaon

along one lineage only – they divide

through cell division to produce new cells

speciﬁc for the ssue of origin, and follow

the body commands. Through the direct

smulaon or replacement of the

recipient’s own malfunconing cells, these

precursor stem cells can deliver

regenerave eﬀect by restoring funcons

to injured, diseased and debilitated ssues

and organs – being a subset of the ulmate

individualised therapy for ssue

regeneraon.

When all convenonal methods of

treatment have been exhausted and in the

prevenon or management therapies of

ongoing challenging condions, the paent

may consider an alternave approach.

Preferably a minimally invasive therapy.

FCTI oﬀers three highly individualised

therapies under physician prescripon for

paents worldwide.

Therapies chosen by praconers are

dependent on the legal frameworks for

pracce and treatment in their respecve

countries.

FCTI does not oﬀer products for sale.

All therapies are paent speciﬁc.

Precursor Stem Cell Therapy through

xenotransplantaon smulates the paent’s

malfunconing damaged or injured cells with new

cells harvested from premium rabbit fetus.

Autologous (self) Stem Cell Therapy sees the

paent’s own blood drawn to extract stem cells

that are reprocessed using highly advanced stem

cell culturing techniques.

FCTI sciensts developed a new approach to

eﬀecvely target and destroy only cancerous cells

while leaving healthy cells unharmed by Acve

Speciﬁc Immunotherapy.

PSCT

ASCT

ASI

FCTI

THERAPIES

FCTI PSCT

LIVER & KIDNEY

FCTI selecvely uses premium rabbits as

the source for its precursor stem cells due

to the abundance in supply, as well as the

discordant genecs of rabbits with human,

which renders an outstanding

compability for long-term therapeuc

administraon into diseased paents. It is

recorded in medical literature that

immune-suppressants are not necessary if

stem cells are prepared by the FCTI

patented preparaon methodology;

Primary Tissue Culture from the fetal

material.

FCTI precursor Stem Cell Therapy PSCT

diﬀers from other fetal stem cell therapies

in its mul-detailed preparaon method of

primary ssue culturing. The fetal stem

cells on their own are limited in their ability

to diﬀerenate into other types of cells.

Rabbits have a natural barrier against

zoonosis transmission. Rabbits have been

ascertained as the only mammal species to

date to have no endogenous retrovirus.

The ssue-speciﬁc precursor stem cells of

FCTI are procured from a European state

cerﬁed closed colony raised for more

than 40 generaons, surpassing WHO and

USFDA requirements.

The handling protocols to meet stringent

prevenon of cruelty guidelines are

cerﬁed by AAALAC Internaonal.

PREMIUM SOURCE

PRECURSOR

STEM CELL

THERAPY

SOURCE SAFETY

FCTI ulises a patented preparaon

methodology – Primary Tissue Culture –

that is a unique cell culturing procedure.

This involves creang an environment of

ideal growth condions for a speciﬁc cell

type of a ssue that is simultaneously

unfavourable for other cell types from the

same ssue that are deemed useless for

the desired therapeuc eﬀect.

This preparaon is necessary for opmal

treatment eﬀect and prevents an angenic

overload.

WORLD LEADING TISSUE CULTURE

TECHNOLOGY

• Daily inspecon by qualiﬁed personnel

• Weekly veterinarian check

PRECURSOR STEM CELL THERAPY

The fundamental scienﬁc principles of

cellular therapy and precursor stem cell

therapy remain;

1. Organ speciﬁcity

2. Homing principle

3. Principle of homology

4. Similarity in genecs

5. Life cycle of cells

6. Phenomenon of paracrine eﬀect

• Documentaon of medical records, full

history & hereditary links

• Bi-annual blood and excreta tesng of

female rabbits

• Full autopsy on each death

• Microbiological tesng

• Bacterial endotoxin test

Samples of blood, brain, bone marrow, liver

and spleen are all obtained and cryogenically

preserved for 5 years

Advantages of Fetal Precursor

Stem Cells over Adult Stem Cells

Advantages of Fetal Precursor Stem Cells over

Embryonic Stem Cells

Fetal Precursor

Embryonic

Unstable due to

oncogenicity

More stableStability

<70 years>85 years cell therapy and

about 1 million paents

treated in Europe

Historical

data

Exist only in a

laboratory dish and

not in a living embryo

Easy and safe

procurement from a fetus

in natural environment

Aainability

Human - very limited

and rare

Animal - abudantly

available

Origin

Self renewal except in

cancer cases

Long term self renewalRenewal

Based on primary

cell culture of dispersed

cells

Based on primary

ssue fragments or cell

clusters

Method of

preparaon

Fetal

Precursor

Adult

Therapeuc

potenal

Low

High

Diﬀerenaon Slow

Fast

Adaptability Low

High

Cell division Slow

Fast

Immunogenicity Higher

Praccally

nil

Survival rate Lower

Higher

Quanty Less

Cells

quality

Numerous

Age

As old as

the host itself

Zero

ensuring the best

quality

What about Umbilical Cord Blood Stem Cells?

Umbilical cord blood is the blood that remains in the umbilical cord and placenta following

birth and aer the cord is cut. Cord Blood is collected because it contains stem cells, which

are genecally unique to the baby and his/her family. However, cord blood has its

limitaon and can only be used generally for the treatment of blood and immune system

disorders.

Umbilical cord blood contains only hematopoiec stem cells and mesenchymal cells but of

no other targeed or speciﬁc organ systems of the body. For that reason, a number of

industry experts have postulated that diseases of central nervous system, digesve system,

excretory system, respiratory system, as well as genec and chromosomal diseases etc.

may not be treated with success by umbilical cord blood stem cells as there is no such

existence of the targeed speciﬁc cells found in umbilical cord blood stemcells nor in the

mesenchyme cells.

It is rather impossible that the only 2 to 3 cell types out of the 220 cell types present in our

bodies can smulate the regeneraon of every organ or ssue. Although the potenal use

of umbilical cord blood is expanding rapidly, the odds are low that family members without

a deﬁned risk will need to use their child’s umbilical cord blood. It contains only a limited

amount of stem cells, which may not be suﬃcient for an adult usage.

Will umbilical cord blood be of guarantee a match for family members or siblings? It is sll

uncertain. Hence, umbilical cord blood stem cells will not guarantee suitable treatment for

all inherited genec diseases.

COMPARATIVE ANALYSIS OF PRECUSOR STEM CELLS WITH OTHER STEM CELLS

FCTI PSCT

PRECURSOR STEM CELL THERAPY

CELL TYPES

FCTI has the producon capacity and know-how to prepare more than 90 types of

precursor stem cells, many of which may not be listed below. The producon of certain

uncommon cell types may be arranged on a request basis.

Placenta (Cytotrophoblast)

Mesenchyme

Thymus

Ly mp h N od e s (M e se n te r ic)

Ovary

Te s s

Prostate

Pituitary

Hypothalamus

Adrenal Cortex

Thyroid

Parathyroid

Peripheral Myoblasts

Smooth Muscle

Osteoblast

Carlage (Arcular)

Synovia

Bone Marrow

Blood (Hematopoiec)

Parasympathicus of Autonomous NS

Spinal Cord

Cauda Equina

Stomach

Gastric Mucosa

Intesnal Mesenchyme

Intesnal Mucosa

Liver

Spleen

Pancreas (Islets)

Pancreas (Exocrine)

Kidney

Lungs

Skin

Heart (Cardiac Myoblast)

Artery

Gingiva

Eye (Rena)

Opc Nerve

Eye Ball

Lobus Occipitalis (Occipital Lobe)

Whole brain (Neural stem cells)

Lobus Frontalis (Frontal Lobe)

Lobus Temporalis (Temporal Lobe)

Lobus Parietalis (Parietal Lobe)

Thalamus

Cerebellum

Medulla Oblongata

Medulla Alba

Hippocampus

Amygdala

Mesencephalon

Rhinencephalon

Basal Ganglia

Synergisc

Cells

Immune

System

Endocrinal

System

Musculoskeletal

System

Hematopoiec

System

Nervous

System

Digesve,

Excretory

and

Respiratory

Systems

Digesve,

Excretory

and

Respiratory

Systems

Cardiovascular

System

Ocular

Tissues

Brain

Tissues

Diencephalon

Brain Stem

Cerebral Cortex

Cerebral Hemisphere

Pineal Gland

FCTI PSCT

CELL TYPES

FCTI PSCT

Age-related Diseases

• Menopause • Depression • Impotence and loss of libido

• Memory loss • Arteriosclerosis • Impaired liver funcon

• Osteoarthrosis • Immune deﬁciency, etc.

Central Nervous System Diseases

• Neurodegenerave disease • Parkinson’s disease

• Demyelinisaon diseases • Old/fresh spinal cord injuries

• Apallic syndrome • Encephalis

• Friedreich’s ataxia • Werdnig-Hoﬀman disease

• Locked-in-syndrome • Amyotrophic lateral sclerosis

• Duchenne & Becker muscular dystrophies • Demena

Ausm

Autoimmune Diseases

• Scleroderma • Rheumatoid arthris • Dermatomyosis

• Systemic lupus erythematosus • Polymyosis

• Sjogren syndrome • Hashimoto’s thyroidis

• Addison’s disease • Chronic acve hepas

• Primary biliary cirrhosis • Glomerulonephris

• Good pasture’s syndrome • Myasthenia gravis

• Bronchial asthma • Pemphigus

• Bullous pemphigoid • Viligo • Atopic dermas

• Autoimmune hemolyc anemia

• Autoimmune thrombocytopaenic purpura

• Pernicious anemia

Chromosomal Disorders

• Down syndrome • Noonan syndrome

• Turner syndrome • Wolf syndrome

Neonatal & Perinatal Diseases

• Cerebral palsy • Inborn errors of metabolism

Endocrine Diseases

• Diabetes mellitus • Vasculopathy

• Adrenocorcal hormonal insuﬃciency

• Premature menopause and andropause

• Retarded puberty • Female inferlity

• Imbalance state of autonomous nervous system

• Endometriosis • Uterine myomas

• Parathyroid insuﬃciency • Hypothyroidism

• Habitual aboron of adrenal eology

Immune System Disorders

• Immunodeﬁciency • Chronic fague syndrome

• Disorder of non-speciﬁc immunity

(e.g. defects of natural killer [N. K.] cells)

Cardiovascular Diseases

• Myocardial infarcon

• Congesve heart failure • Peripheral arterial disease

• Chronic cardiac disorder

• Arterioscleroc vascular disease

Liver Diseases

• Liver cirrhosis • Chronic hepas • Fay Liver disease

• Crigler-Najjar syndrome • Primary Biliary cirrhosis

• Non-alcoholic steatohepas (NASH)

Kidney Diseases

• Genec diseases of renal tubules

• Nephroc syndrome • Glomerular disease

• Chronic Kidney Disease stage 1-4

Lung Diseases

Locomotor System Diseases

• Non-healing fractures • Osteoarthrosis

• Pulmonary ﬁbrosis • Emphysema

• Chronic osteomyelis • Osteogenesis imperfecta

• Achondroplasia

• Arthrogryposis mulplex • Chronic osteomyelis

• Chronic arthris • Rheumatoid arthris • Osteoporosis

Metabolic Diseases

• Atherosclerosis • Lipoprotein metabolism disorder

• A-β-lipoproteinemia

Digesve System Diseases

• Atrophic gastris • Chronic pancreas

• Malabsorpon syndrome

Genec Diseases

• Wilson’s disease • Muscular dystrophy

• Cornelia-de-Lange syndrome • Gaucher disease

• Metachromac leukodystrophy • Fabry’s disease

• Gangliosidoses • Refsum disease

• Neuroﬁbromatosis • Tuberous sclerosis

• Mitochondrial genec disease

Skin Diseases

• Deep burns

• Acne vulgaris • Ulcus cruris • Various eczemas

• Sarcoid Darier-Roussy • Hereditary keratosis

• Palmaris et plantaris • Chronic lichen • Scleroderma

• Alopecia areata

Radiaon Injuries

e.g. Post radiaon ulcers

Hematological Diseases

• Thalassemias • Sickle cell anemia • Aplasc anemias

• Hereditary hemolyc anemias • Thrombocytopaenias

• Erythropoiesis disorder • Primary hemachromatosis

• Werlhof disease

INDICATIONS

AUTISM

DOWN SYNDROME

FCTI PSCT

AUTISM & DOWN SYNDROME

Ausm is a brain development disorder characterised by impaired social interacon and

communicaon, and by repeve and restricted behavior. It is believed to have a strong

genec basis and much contemporary argument points towards links to immunisaon.

Heavy metals are found in the mothers of many ausc children perhaps due to exposure

to chemicals like paint, pescides, new furniture or carpet during pregnancy. 2016 data

concludes perhaps as many as in 60 children are aﬀected with the USA then China the

world’s leading aﬀected countries.

A condion caused by an error in cell

division that results in chromosomal

abnormalies, generally in one in every

700 births; much higher in the middle east.

As a woman’s age increases, the risk

heightens in carrying a child with Down

Syndrome. Physical development occurs at

a lower rate because of weak and ﬂoppy

muscles. Speech is delayed yet paents

can normally live to 60 with normal ferlity

and the capacity for oﬀspring.

In pre-1957 German, Spain, Russia, select

European states and the USA, documented

PSCT therapy applied before the age of 13

proved stascally signiﬁcant

improvement in height, IQ, concentraon,

speech, motor skills and immune system.

Down Syndrome is one condion that

responds well to PSCT. Early intervenon of

down syndrome in infants and children with

FCTI PSCT can make a diﬀerence in

maximising their potenal ability for a beer

quality of life.

Cerebral cortex

a thin layer of gray maer

on the surface of the

cerebral hemispheres. Two

thirds of its area is deep in

the ﬁssures or folds.

Responsible for the higher

mental funcons, general

movement, percepon and

behavioral reacons.

Basal ganglia

gray masses deep in

the cerebral

hemisphere that

serves as a

connecon between

the cerebrum and

cerebellum. Helps to

regulate automac

movement.

Hippocampus

makes it possible to

remember new

informaon and

recent events.

Amygdala

responsible for

emoonal responses,

including aggresive

behavior.

Cerebellum

located at the back of the brain,

it ﬁne tunes our motor acvity,

regulates balance, body

movements, coordinaon, and

the muscles used in speaking.

consists primarily of closely packed bundles

of ﬁbers that connect the right and le

hemisphere and allows for communicaon

between the hemispheres

Corpus callosum

White maer

consists of the ﬁbers that connect one

nerve cell to another. Decrease of

White maer density is an early sign of

the risk of Ausm development.

½ years old

½ years old 10 years old

½ years old 3 years old 10 years old

From ½ years old to 10 years old with controlled,

clear facial expression, speaks ﬂuently, read

books and writes accurately.

DIABETES & CEREBRAL PALSY

DIABETES

CEREBRAL PALSY

FCTI PSCT

Absence or insuﬃcient producon of

insulin causes diabetes. The two types of

diabetes are referred to as type 1

(insulin-dependent, juvenile onset) and

type 2 (non-insulin-dependent, adult

onset).

Diabetes remains one of the most common

chronic medical condions threatening the

modern world. In China, the prevalence

has more than quadrupled in recent

decades where paents have at least twice

the increased risk of mortality due to

ischemic heart disease, stroke, chronic

liver disease, and infecon

PSCT has shown eﬀecveness slowing the progress of diabec complicaon. The sooner a

paent receives PSCT aer diagnosis the success rate of the therapy proves greater. Especially

children with diagnosed type 1, able to signiﬁcantly delay the progression of diabec

complicaons that are deleterious to their growth and development.

Also for diabec women on ferlity treatment for more than a year without success, PSCT is a

strong therapeuc consideraon. If a pregnant diabec woman delivers a baby with diabec

fetal distress syndrome, PSCT is oen recommended before the next pregnancy or even during

the pregnancy between 12th and 16th weeks.

Cerebral Palsy (CP) is a disorder that

aﬀects muscle tone, movement, and motor

skills (the ability to move in a coordinated

and purposeful way). CP usually is caused

by brain damage that happens before or

during a baby's birth, or during the ﬁrst 3

to 5 years of a child's life. The abnormality

in the motor system is a result of

non-progressive brain lesions.

PSCT has shown great beneﬁt for CP

paents, speciﬁcally for;

• Spasc forms that respond to intensive

forms of physical training

(possible up to 10 years old);

• Dyskinec forms – choreoathetosis and

ataxic form (possible up to 10 years old);

• Hypotonic forms -

(possible up to 4 years old)

The age at which PSCT is introduced can be a

signiﬁcant factor. The earlier the PSCT, the

beer chance children have overcoming

developmental disabilies or learning new

ways to accomplish the tasks that challenge

them daily.

PARKINSON’S DISEASE

AGE RELATED DISEASE

HEART DISEASE

FCTI PSCT

PD is an degenerave disorder of the

central nervous system that oen impairs

the paent’s motor skills, speech and other

funcons. PSCT has shown great promise

in helping regenerate the central nervous

system. For Parkinsons paents in

parcular, the neurons that die are

responsible for connecng a structure in

the brain. Such neuronal connecons allow

for releases of the chemical transmier

dopamine onto their target neurons in the

striatum, which controls body movement.

It is the regeneraon of the

dopamine-producing neurons that

restores normal body movement.

PSCT has been shown to be eﬀecve

assisng this regeneraon.

Ageing is an accumulaon of damage in an

organism over me to macromolecules,

cells, ssues and organs. As we grow older

our bodies’ ability to repair and regenerate

starts to decline. Wrinkles, loss of elascity

in skin tone, sﬀ joints, loss of bone and

muscle mass, and loss of hearing are some

age-related issues everyone experiences.

As cells progressively weaken over me and

die, PSCT can work to remediate aging by

treang, slow and reverse age related

disease. The prime age to commence

regenerave therapy is age 35.

*improved mental and physical acvity

*increased vitality & metabolism

*quality sleeping paerns

*reduced wrinkles *healthier skin colour

*enhanced blood circulaon

*improved appete

PSCT is a therapeuc answer for a variety of heart condions and disease.

as well as :

CORONARY THROMBOSIS

An area of plaque becomes roughened,

because of ﬁbrous covering tears. Blood

cells, especially platelets, begin to sck to

the area and trigger the formaon of a

thrombus (clot).

Ruptured

ﬁbrous

cover

Aorta

Superior

vena cava

Pulmonary

artery

Right

coronary

artery

Le main

coronary

artery

Damaged

muscle

Narrowed

artery

Damaged

muscle

Enzymes

released

Site of

blockage

Blood

supply

to vessels

blocked

Necroc (dead)

muscle ﬁbres

Blood clot

MYOCARDIAL INFARCTION

When a coronary artery becomes blocked, the cells of the

heart muscle it supplies begin to die from the lack of

oxygen and nutrients and the accumulaon of poisonous

waste products. FCTI products can possibly complement

its recovery aer myocardial infarcon.

ENZYME RELEASE

Degenerang muscle ﬁbres

in the aﬀected area release

a number of enzymes into

the circulaon. Measuring

these enzymes through a

blood test indicates the

extent of the heart muscle

damage.

DAMAGED HEART

MUSCLE

If cells are deprived of

oxygen and nutrients, they

quickly degenerate. If the

blood supply is not

restored quickly, the ssue

eventually dies, a process

known as necrosis. At this

stage, the damage to the

cells is irreversible.

INTRACTABLE ARRHYTHMIA

CONGESTIVE HEART FAILURE

PERIPHERAL ARTERIAL DISEASE

ARTERIOSCLEROTIC VASCULAR DISEASE

PARKINSONS, AGE RELATED, HEART

Aer PSCT, some beneﬁts may include:

LIVER DISEASE

KIDNEY DISEASE

PSCT is a treatment of choice for a variety of liver disease including

• Fay Liver disease • Primary biliary cirrhosis

• Crigler-Najjar syndrome • Non-alcoholic steatohepasis (NASH)

Hepas, is an inﬂammaon of

the liver, caused mainly by

viruses. However, alcohol, toxins,

immune deﬁciency, and immune

imbalance play an important role

in damage of the liver too.

Cirrhosis is a result of the

excessive formaon of the

ﬁbrous ssues in the liver that

aﬀect liver’s structure and

funcon. Chronic viral or toxic

hepas, accompanied by the

auto-immune mechanisms are

the main reasons of the Liver

Cirrhosis.

The main causes of kidney

failure are:

• Diabetes

• Hypertension

• Autoimmune diseases

• Kidney stone

There are two types of kidney injury: acute and chronic.

The kidneys perform a number of funcons, chieﬂy ﬁltering the blood, removing waste by

creang urine, adjusng the chemical and ﬂuid balance in the body by controlling the

concentraon of urine, and parcipang in the control of blood pressure.

Le

kidney

Abdominal

aorta

Renal artery

Inferior

vena kava

Renal pelvis

Ureter

Cortex

Medulla

(Pyramids)

Major

calyces

Minor

calyces

Right

kidney

Secon view

Gallbladder

Liver

Bile duct

Hepac arteries

Portal vein

Aorta

Central vein

system

Hepac vein

FCTI PSCT

LIVER & KIDNEY

THERAPEUTIC PROCESS

• Doctor consultaon with paent.

• Doctor completes medical report and FCTI standard medical

quesonnaire.

• FCTI medical advisors prescribe appropriate cytobiological

therapy.

• Doctor consults paent with recommended therapy.

• Paent decides.

Consult

Post care

• Doctor follows up with paent regularly and reports progress

every 4 months to FCTI

• PSCT must be performed within 72 hours of cell culture

compleon in Europe.

Implantaon

• Payment is conﬁrmed 21 days before implantaon.

• Individualised therapy is prepared using proprietary culturing

method in Europe.

• Tissue culturing requires 11 days, commencing 22 days

before therapy.

• Precursor Stem Cells are hand carried to end desnaon

worldwide.

Culturing & Preparaon

FCTI PSCT

PRODUCTION PROCESS

FCTI ASCT

ASCT

THERAPY

PRODUCTION PROCESS

Autologous or ‘Self’ Stem Cell Therapy gives greater choice to Doctors and paents who

believe stem cell therapy may alleviate their symptoms, but remain concerned about safety

issues or are unconvinced of the beneﬁts of xenotransplantaon.

ASCT is produced from taking the paent’s own blood, harvesng their stem cells, the

culturing the cells using proprietary ssue culturing methodology.

AUTOLOGOUS STEM CELL THERAPY

• Doctor consultaon with paent.

• Doctor completes medical report and FCTI standard medical

quesonnaire.

• 5cc of blood is taken from adult paents/3cc from child paents.

Consult

Post care

• Doctor follows up with paent regularly and reports progress

every 4 months to FCTI.

• ASCT must be performed within 72 hours of cell culture

compleon in Europe.

Implantaon

• Payment is conﬁrmed 21 days before implantaon.

• Blood is collected by medical biohazard courier and hand

carried to Europe.

• Individualised therapy is prepared by segregang stem cells

from blood cells then using proprietary culturing method.

• Tissue culturing requires 20 days intensive preparatory work.

• The autologous ‘Self’ Stem Cells are hand carried to paent’s

Doctor.

Culturing & Preparaon

FCTI ASI

Acve Speciﬁc Immunotherapy (ASI®) is

one of the most recent advances in cancer

tumour therapy in this modern integrave

medical ﬁeld.

ASI® is a form of complementary /

alternave therapy to improve immunity at

the various stages of the disease.

The ASI® foundaon is based on the fact

that the immune system is the best tool in

combang disease.

This concept modulates the immune

system to achieve an antumour response

with tumour-associated angens as the

immunizing materials.

It potenally helps ﬁght cancer and other

diseases of the immune system.

Recent clinical studies reﬂect the

eﬀecveness of immunotherapy in

combinaon with complementary

therapies as a potenal approach to

speciﬁcally target cancer cells without

causing any harm to the immune system.

Further immunologic studies have shown

that cancer is not only a cellular disorder

triggered by false genec informaon but

also an immunologic issue.

One of the major beneﬁts of

Immunotherapy is that it does not display

any form of toxicity.

In addion, it oﬀers a diﬀerent mode of

aack on the tumour by strengthening the

immune system.

ASI® is most commonly used for cancers

of :

• Liver • Prostate

• Stomach • Intesne

• Pancreas • Lymph glands

• Breast • Melanblastomas

FCTI ASI THERAPY

Dr. Rudolph Pekar

Acve Speciﬁc Immunotherapy (ASI®)

is a therapy patented by the Edith

Liebergeld Instute in Germany.

ASI® was developed by Dr. Rudolph

Pekar; a renowned Austrian cell

therapist and expert on

bioelectrotherapy.

ACTIVE SPECIFIC IMMUNOTHERAPY

FCTI ASI

IMMUNE SYSTEM

The human immune system is made up of a network of

cells, ssues and organs and is a system of biological

structures and processes within an organism that work

together to protect the body against the invasion of

bacteria, viruses, parasites and other diseases.

IMMUNE SYSTEM DISORDERS

1. Immunodeﬁciency disorders

Primary immunodeﬁciencies are disorders in which part of the body’s immune system is not

present or working properly. Most are hereditary, autosomal recessive or X-linked eﬀecng

1 in 500 at birth.

Secondary or acquired immunodeﬁciencies are the result of external processes –

malnutrion, ageing, medicaon like immunosuppressive drugs or chemotherapy - or via

infecon.

2. Allergic Disorders

Allergic disorders occur when the immune system over reacts aer exposure to angens.

These include asthma, eczema or speciﬁc environmental allergies (dust mites) drug

allergies, seasonal allergies (hay fever) and food allergies (nuts).

3. Cancers of the immune system

Leukemia and lymphoma are both cancers of the immune system.

4. Autoimmunity

This refers to the failure of an organism to recognise its own parts, which causes a mistaken

immune system response against its own cells or ssues. These include insulin dependent

diabetes, rheumatoid arthris and systemic lupus erythematosus.

When foreign substances or angens are detected

invading the body, several types of cells work together

to recognise and respond to them. These cells trigger

the B lymphocytes (the main type of immune cells) to

produce anbodies into bodily ﬂuids. Once produced,

these anbodies remain in the body so that when the

same angen reappears, the anbodies replicate the

funcon. An anbody will interlock with an angen and

mark the angen for destrucon. They are not able to

destroy any angen without seeking assistance from T

cells, which act like soldiers aacking and destroying

the invaders. T lymphocytes work primarily by secreng

a potent chemical known as lymphokines. Binding to

target cells, lymphokines mobilise other cells,

encouraging cell growth, acvity, mobility and

eliminate target cells.

IMMUNOLOGY

FCTI ASI

ANTI-AGEING

• Hypothyroidism/Autoimmune Thyroidis

• Polyarthris • Rheumatoid arthris

AUTOIMMUNE DISEASE

SKIN DISEASE

• Colis

• Crohn’s disease

• Allergic Rhinis

• Allergic dermas

• Sinusis

• Dermatomyosis

• Scleroderma

• Prevenon • Early stage • Late stage

• Acne

IMMUNOTHERAPY AS COMPLEMENTARY THERAPY FOR CANCER

ALLERGIES

• Bronchial asthma

• Psoriasis

• Eczema

• Keratosis

INDICATIONS

• Pemphigus

• 30ml of blood is drawn from paent in 3 x 10ml syringes

• syringe posioned vercally with piston facing down at room temperature

• labelled correctly with paent data, name & DOB

• biohazard courier directly to German laboratory within 24 hours

• laboratory receipt & treatment under sterile condions

(GMP standard laminar-ﬂow technique)

• isolaon of Buﬀy-coat

• separaon of Buﬀy-coat elements & biochemical treatment

• addion of immune acvang substances

• ozone boosng therapy

• preparaon of 30 x 1.1ml vials for alternate daily subcutaneous injecon

• or (dependent on Doctor’s recommendaon)

• 3 x 10ml vials for weekly subcutaneous injecon

BLOOD FOR ANTI AGEING AND EARLY STAGE CANCER

TUMOUR TISSUE FOR LATE STAGE CANCER

• Tumour ssue removed (5-10 grams; about the size of ﬁngerp) during surgery

• Preferably not exposed to radiaon

• If undergoing chemotherapy, 2 weeks must lapse prior to sample acquision

• Tissue stored in small sterile pipe in refrigerator (not to be frozen)

• Biohazard courier directly to German laboratory within 12 hours at 4-8 degrees C

• Laboratory receipt & treatment under sterile condions

(GMP standard laminar-ﬂow technique)

• Separaon of elements & biochemical treatment

• Addion of immune acvang substances

• Ozone boosng therapy

• Preparaon of 1 x 30ml vial for single dose subcutaneous injecon

• or (dependent on Doctor’s recommendaon)

• Manufacture of speciﬁc-acve preparaon for a series of injecons of graded

cytoplasmic cell wall fracons, protoplasms (without nucleic acid and deacvated

tumour commensals)

FCTI ASI

PRODUCTION PROCESS & APPLICATION

The buﬀy coat is the fracon of an ancoagulated blood sample that contains

most of the white blood cells and platelets following density gradient

centrifugaon of the blood.

www.fcinc.com

For more informaon please visit:

Precursor Progenitor

Stem Cell Therapy